Recommendation of the President – Milupa Basic-f

On 13 Septeber 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 92/2024 on the legitimacy of authorizing the reimbursement of Milupa Basic-f in the following indications: CACT deficiency, VLCAD deficiency, lymphangioleiomyomatosis (including condition after cardiac surgery), abetalipoproteinemia, lipid metabolism disorders (hypercholesterolemia and hypertriglyceridemia), lipoprotein lipase deficiency.

Publication in Public Information Bulletin (BIP) >>